Supplementary File 1: Proteomic and Mechanistic Study on Clove and Eugenol for Psoriasis

759.0 KB supplementary document details a proteomic study on the anti-psoriatic effects of clove extract and its major constituent eugenol (65.8%). The research used an imiquimod-induced mouse model and proteomic analysis to identify modulation of the IL-36/IL-17A axis and NF-κB signaling. The document, authored by Tin-Yun Ho, was last updated on 2026-05-26 and is shared under a CC-BY-4.0 license.

Use Cases

• Analyzing proteomic alterations in psoriasis models based on the described LC-MS/MS and bioinformatics workflow.
• Investigating molecular docking interactions between eugenol and IL-17A based on the described competitive binding assays.
• Studying the modulation of IL-36 and IL-17 signaling pathways in inflammatory skin disorders based on the described immunohistochemistry results.

Strengths

• The description provides a specific, quantitative finding: eugenol constitutes 65.8% of the clove extract.
• The study employs multiple validation methods described in detail: proteomics, competitive binding assays, molecular docking, and immunohistochemistry.

Limitations

• The dataset is a 759.0 KB DOCX file, which is a small supplementary document rather than a primary data repository.
• Row count and column-level documentation are absent; data structure and semantics must be inferred from the document text.
• The data is derived from a specific mouse model (imiquimod-induced), which may limit direct applicability to human psoriasis.

Provenance

Source

figshare

Collection Method

Proteomic analysis via isobaric tags for relative and absolute quantitation-based LC-MS/MS, bioinformatics, and in vitro assays.

Freshness

Last updated 2026-05-26 04:37:19; freshness should be verified.